Skip to main content

What Tempus AI's Quarter ended Sep 30, 2026 10-Q says: 5 signals

Tempus AI filed its latest 10-Q with the SEC on Nov 2, 2026. It discusses acquisition announced, acquisition completed and AI investment.

Public (TEM)Biotechnology Research5,001 to 10,000 employeestempus.comLinkedIn

Get Tempus AI's live signals in Claude or ChatGPT, or by API

AskWhat changed at Tempus AI this week? Use Autobound signals for tempus.com.
Filed
Nov 2, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
25

Source: Autobound Signal API · 98 signals tracked for Tempus AI · updated

10-Q · latest 10

What Tempus AI's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 5 signals

    SEC EDGAR
  2. 10-Q

    Filed · 8 signals

    SEC EDGAR

Earlier 10-Q filings

Showing 10 of 25 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Tempus AI earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Actively procuring additional GPU capacity for large-scale AI model trainingThe company is doubling down on its AI foundation model, moving into the 'large compute' phase and actively seeking more GPU capacity. This represents a significant, immediate IT and cloud infrastructure spending initiative.
Struggling with NGS sequencing failures and insufficient sample material (QNS)Leadership explicitly acknowledged that a percentage of their sequencing tests fail due to technical issues or lack of sufficient biological material. They are actively seeking technological solutions, like the newly acquired Paige AI, to mitigate this core operational problem.
Aspires to an 'NVIDIA moment' by monetizing diagnostic algorithmsThe CEO's long-term vision is to move beyond wet lab services and achieve exponential growth by distributing and monetizing AI-driven diagnostic algorithms. This software-centric, scalable model underpins their heavy investments in data, AI, and compute infrastructure.
Overcame significant sales force disruption, now focused on efficiencyThe CEO admitted that previous changes to the sales force 'caused havoc' but are now resolved. The current focus is on sales force efficiency and leveraging their integrated technology, indicating a receptiveness to tools that enhance sales productivity and effectiveness.
Investing heavily in R&D for next-generation MRD assays and new clinical studies.The company is running new studies for a more sensitive tumor-naive MRD assay in lung cancer and CRC, indicating significant R&D spend. This focus on developing a highly competitive product portfolio creates needs for clinical trial support, data analysis tools, and lab technologies.
Planning FDA submission for xF liquid biopsy test, a key strategic initiative.The company is preparing to file for FDA approval for its xF liquid biopsy test this year, a major regulatory and commercial initiative. This effort will require significant resources and is a critical step toward securing higher reimbursement (ADLT status) and driving future revenue growth.

Signal API · MCP

Track Tempus AI with the Signal API

One POST /v1/companies/enrich call with tempus.com returns Tempus AI 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"tempus.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Company pages

Questions about Tempus AI 10-Q

When did Tempus AI file its latest 10-Q?
Tempus AI filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 2, 2026. The one before it was filed on Jul 30, 2026.
What did Tempus AI disclose in its latest 10-Q?
From the filing dated Nov 2, 2026: Tempus Collaborates with AstraZeneca and Pathos to Build Foundation Multimodal Oncology AI Model
What did Tempus AI say on its recent earnings calls?
Q3 FY2025: Actively procuring additional GPU capacity for large-scale AI model training (dated Nov 4, 2025).
Where can I read Tempus AI's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1717115/000119312526442624/tem-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →